Cytokinetics gets bump after DMC says CVOT should proceed

Cytokinetics added $1.63 (19%) to $10.19 on Wednesday after it said a DMC recommended the Phase III GALACTIC-HF cardiovascular outcomes trial of omecamtiv mecarbil continue without changes following a planned interim analysis, which included a prespecified futility analysis. The trial is evaluating the cardiac myosin activator compared with placebo to reduce the risk of CV death and heart failure events.

GALACTIC-HF has enrolled over 7,000 patients with chronic heart failure with reduced ejection fraction. Cytokinetics Inc. (NASDAQ:CYTK) said it plans to complete enrollment of about 8,000 patients this half...